Key result
Patients with diabetes mellitus exhibit higher resistance to acetylsalicylic acid (up to 71.4%) and clopidogrel (up to 57.1%), necessitating tailored antithrombotic therapies based on cardiovascular and renal risks.
Why the study?
Patients with diabetes mellitus have a high risk of thrombosis regardless of cardiovascular disease, along with higher resistance to standard antiplatelet therapy.
This review highlights the specific challenges of antithrombotic therapy in diabetic patients, such as higher antiplatelet resistance, and summarizes current guideline recommendations for their management across various cardiovascular conditions.
Answers are grounded in this paper and cite their sources.
May inform individualized regimens in diabetes; hypothesis-generating pending randomized outcome trials.
The study discussed various possibilities of antithrombotic therapy in patients with diabetes mellitus. Patients with diabetes mellitus, regardless of whether they have cardiovascular diseases, have a high risk of thrombosis. A feature of the response to antiplatelet therapy is the higher resistance to acetylsalicylic acid and clopidogrel of patients with diabetes mellitus than patients without diabetes mellitus, which can reach 71.4% and 57.1%, respectively. With a decrease in the functional ability of the kidneys in patients with diabetic nephropathy, acetylsalicylic acid is a safe antiplatelet drug; the use of clopidogrel in these patients leads to an increase in the risk of general and cardiovascular mortality. In the absence of contraindications, acetylsalicylic acid is recommended for patients with diabetes mellitus for the secondary prevention of cardiovascular diseases and may be recommended for primary prevention in patients with high and very high cardiovascular risk. Clopidogrel is recommended for patients with diabetes mellitus only for the secondary prevention of intolerance to acetylsalicylic acid. With the development of acute coronary syndrome, patients with diabetes mellitus received double antiplatelet therapy using acetylsalicylic acid and any P2Y12 receptor blocker. In patients who received percutaneous coronary intervention, prasugrel or ticagrelor is recommended as the second component. Double antiplatelet therapy extended for 12 months is indicated for patients with diabetes mellitus with a very high cardiovascular risk and good tolerability. In non-valvular atrial fibrillation, direct oral anticoagulants, in the absence of contraindications, are the drugs of choice in patients with diabetes and creatinine clearance 30 mL/min for dabigatran and 15 mL/min for rivaroxaban and apixaban. With the development of terminal renal insufficiency, only warfarin has proven effectiveness. Combined antiplatelet and anticoagulant therapy is indicated for diabetes mellitus with coexisting atherosclerotic diseases with a high risk of thrombotic and low risk of hemorrhagic complications.
No takes yet. Share an insight, caveat, or question.
Kryukov et al. (2023) conducted a review in Diabetes mellitus. Antithrombotic therapy was evaluated. Patients with diabetes mellitus exhibit higher resistance to acetylsalicylic acid (up to 71.4%) and clopidogrel (up to 57.1%), necessitating tailored antithrombotic therapies based on cardiovascular and renal risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: